Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Core Insights - Tenaya Therapeutics has received an $8.0 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support the ongoing Phase 1b RIDGE-1 clinical trial of TN-401 gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) [2][4] - The RIDGE-1 trial aims to evaluate the safety, tolerability, and preliminary clinical efficacy of TN-401, which is designed to deliver a functional PKP2 gene to heart muscle cells [3][4] - Initial data from the RIDGE-1 trial is expected in the second half of 2025 [1][4] Company Overview - Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease [12] - The company is advancing a portfolio of genetic medicines, including TN-401 for PKP2-associated ARVC and TN-201 for MYBPC3-associated hypertrophic cardiomyopathy [12] Clinical Trial Details - The RIDGE-1 clinical trial is an open-label, dose-escalation study enrolling symptomatic adults diagnosed with PKP2-associated ARVC [3][4] - TN-401 utilizes an adeno-associated virus serotype 9 (AAV9) vector for gene delivery, which has a strong safety record and targets heart muscle cells effectively [7][9] Disease Background - PKP2 mutations are the most common genetic cause of ARVC, affecting approximately 70,000 people in the U.S. [5][6] - Current treatments for ARVC do not address the underlying genetic cause, highlighting the potential significance of TN-401 as a novel therapeutic approach [6][9] Funding and Support - CIRM has been instrumental in funding regenerative medicine research, having provided billions since its establishment in 2004 [10][11] - The grant awarded to Tenaya Therapeutics is part of CIRM's efforts to accelerate the development of transformative treatments for serious medical conditions [4][10]